{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:52:20Z","timestamp":1795161140956,"version":"4.10.3"},"reference-count":398,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4S","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1097\/tp.0000000000001651","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T06:23:01Z","timestamp":1490250181000},"page":"S1-S56","source":"Crossref","is-referenced-by-count":293,"title":["Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients"],"prefix":"10.1097","volume":"101","author":[{"given":"James M.","family":"Neuberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf O.","family":"Bechstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk R.J.","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Citterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"De Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Duvoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard K.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herold J.","family":"Metselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Pirenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel L.","family":"Rodr\u00edguez-Per\u00e1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schneeberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ser\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Trune\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tisone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210211","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/TP.0b013e318292827f","article-title":"Who fares worse after liver transplantation? Impact of donor and recipient variables on outcome: data from a prospective study","volume":"95","author":"Gambato","year":"2013","journal-title":"Transplantation"},{"key":"R2-1-20210211","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)60699-5","article-title":"Diagnosis and prevention of chronic kidney allograft loss","volume":"378","author":"Nankivell","year":"2011","journal-title":"Lancet"},{"key":"R3-1-20210211","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/TP.0b013e3182708ea8","article-title":"Kidney graft survival in Europe and the United States: strikingly different long-term outcomes","volume":"95","author":"Gondos","year":"2013","journal-title":"Transplantation"},{"key":"R5-1-20210211","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ckj\/sfv151","article-title":"Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus","volume":"9","author":"Kramer","year":"2016","journal-title":"Clin Kidney J"},{"key":"R7-1-20210211","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/bja\/aer384","article-title":"Organ transplantation: historical perspective and current practice","volume":"108","author":"Watson","year":"2012","journal-title":"Br J Anaesth"},{"key":"R8-1-20210211","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.3748\/wjg.v22.i21.4966","article-title":"How important is donor age in liver transplantation?","volume":"22","author":"Lu\u00e9","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R9-1-20210211","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfr524","article-title":"Age is an important predictor of kidney transplantation outcome","volume":"27","author":"Veroux","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R10-1-20210211","first-page":"81","article-title":"Clinical and economic consequences of non-adherence to immunosuppressive drugs in adult solid organ transplantation.","volume":"63-","author":"De Geest","year":"2011","journal-title":"Int Transplant Updat"},{"key":"R11-1-20210211","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-6143.2008.02495.x","article-title":"Nonadherence consensus conference summary report","volume":"9","author":"Fine","year":"2009","journal-title":"Am J Transplant"},{"key":"R12-1-20210211","doi-asserted-by":"crossref","first-page":"58","DOI":"10.12968\/jorn.2010.2.2.47252","article-title":"Immunosuppressive drugs and non-adherence in transplantation","volume":"2","author":"De Geest","year":"2010","journal-title":"J Ren Nurs"},{"key":"R13-1-20210211","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lt.21891","article-title":"What is the real gain after liver transplantation?","volume":"15","author":"Neuberger","year":"2009","journal-title":"Liver Transpl"},{"key":"R14-1-20210211","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.2006.093195","article-title":"Life expectancy of adult liver allograft recipients in the UK","volume":"56","author":"Barber","year":"2007","journal-title":"Gut"},{"key":"R15-1-20210211","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000070864","article-title":"Death with functioning graft in living donor kidney transplantation: analysis of risk factors","volume":"23","author":"El-Agroudy","year":"2003","journal-title":"Am J Nephrol"},{"key":"R16-1-20210211","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.transproceed.2004.08.086","article-title":"Analysis of cause of death with a functioning graft: a single-center experience","volume":"36","author":"Shimmura","year":"2004","journal-title":"Transplant Proc"},{"key":"R17-1-20210211","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/TP.0b013e31821841ba","article-title":"The pattern of late mortality in liver transplant recipients in the United Kingdom","volume":"91","author":"Gelson","year":"2011","journal-title":"Transplantation"},{"key":"R18-1-20210211","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.2215\/CJN.03040707","article-title":"Late kidney allograft loss: what we know about it, and what we can do about it","volume":"3","author":"Jevnikar","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-1-20210211","first-page":"457","article-title":"Drug-induced impairment of renal function","volume":"7","author":"Pazhayattil","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"R20-1-20210211","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"R21-1-20210211","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R22-1-20210211","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3389\/fimmu.2016.00646","article-title":"Lymphoid neogenesis and tertiary lymphoid organs in transplanted organs","volume":"7","author":"Koenig","year":"2016","journal-title":"Front Immunol"},{"key":"R23-1-20210211","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-62703-493-7_2","article-title":"Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury","volume":"1034","author":"Valenzuela","year":"2013","journal-title":"Methods Mol Biol"},{"key":"R24-1-20210211","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1600-6143.2011.03754.x","article-title":"Delayed graft function in the kidney transplant","volume":"11","author":"Siedlecki","year":"2011","journal-title":"Am J Transplant"},{"key":"R25-1-20210211","doi-asserted-by":"crossref","first-page":"193724","DOI":"10.1155\/2012\/193724","article-title":"Antibody-mediated rejection in kidney transplantation: a review","volume":"2012","author":"Puttarajappa","year":"2012","journal-title":"J Transplant"},{"key":"R26-1-20210211","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2011.03.005","article-title":"What is the long-term outcome of the liver allograft?","volume":"55","author":"H\u00fcbscher","year":"2011","journal-title":"J Hepatol"},{"key":"R27-1-20210211","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1600-6143.2008.02541.x","article-title":"Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors","volume":"9","author":"Bekker","year":"2009","journal-title":"Am J Transplant"},{"key":"R28-1-20210211","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajt.12667","article-title":"The role of donor-specific HLA alloantibodies in liver transplantation","volume":"14","author":"O\u2019Leary","year":"2014","journal-title":"Am J Transplant"},{"key":"R29-1-20210211","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/lt.23930","article-title":"Medication level variability index predicts rejection, possibly due to nonadherence, in adult liver transplant recipients","volume":"20","author":"Supelana","year":"2014","journal-title":"Liver Transpl"},{"key":"R30-1-20210211","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/lt.23743","article-title":"How important is acute cellular rejection?","volume":"19","author":"Charlton","year":"2013","journal-title":"Liver Transpl"},{"key":"R31-1-20210211","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa0706992","article-title":"Hepatitis E virus and chronic hepatitis in organ-transplant recipients","volume":"358","author":"Kamar","year":"2008","journal-title":"N Engl J Med"},{"key":"R32-1-20210211","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/ajt.13060","article-title":"Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry","volume":"15","author":"Adam","year":"2015","journal-title":"Am J Transplant"},{"key":"R33-1-20210211","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1600-6143.2010.03179.x","article-title":"A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation","volume":"10","author":"Irish","year":"2010","journal-title":"Am J Transplant"},{"key":"R34-1-20210211","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra011295","article-title":"Strategies to improve long-term outcomes after renal transplantation","volume":"346","author":"Pascual","year":"2002","journal-title":"N Engl J Med"},{"key":"R35-1-20210211","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10620-012-2412-0","article-title":"Non-adherence and graft failure in adult liver transplant recipients","volume":"58","author":"Lieber","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"2014","key":"R36-1-20210211","first-page":"5","article-title":"CTS Collaborative Transplant Study Newsletter.","volume":"1","author":"Opelz","year":"2014","journal-title":""},{"key":"R37-1-20210211","doi-asserted-by":"crossref","first-page":"11363","DOI":"10.3748\/wjg.v20.i32.11363","article-title":"\u201cMinimizing tacrolimus\u201d strategy and long-term survival after liver transplantation","volume":"20","author":"Jia","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R38-1-20210211","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","article-title":"High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation","volume":"25","author":"Borra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R39-1-20210211","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/ajt.12212","article-title":"De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients","volume":"13","author":"Kaneku","year":"2013","journal-title":"Am J Transplant"},{"key":"R40-1-20210211","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/tri.12654","article-title":"De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients","volume":"28","author":"Del Bello","year":"2015","journal-title":"Transpl Int"},{"key":"R41-1-20210211","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/ajt.12651","article-title":"Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients","volume":"14","author":"Del Bello","year":"2014","journal-title":"Am J Transplant"},{"key":"R42-1-20210211","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/TP.0b013e31826e592e","article-title":"Calcineurin inhibition and new-onset diabetes mellitus after transplantation","volume":"95","author":"Chakkera","year":"2013","journal-title":"Transplantation"},{"key":"R43-1-20210211","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/ajt.12090","article-title":"The impact of meeting donor management goals on the development of delayed graft function in kidney transplant recipients","volume":"13","author":"Malinoski","year":"2013","journal-title":"Am J Transplant"},{"key":"R44-1-20210211","doi-asserted-by":"crossref","first-page":"750579","DOI":"10.1155\/2014\/750579","article-title":"Validity of cardiovascular risk prediction models in kidney transplant recipients","volume":"2014","author":"Mansell","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"R45-1-20210211","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1111\/j.1600-6143.2009.02917.x","article-title":"Guidelines for vaccination of solid organ transplant candidates and recipients","volume":"9","author":"Danzinger-Isakov","year":"2009","journal-title":"Am J Transplant"},{"key":"R46-1-20210211","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/FTD.0b013e3182708edf","article-title":"Pharmacokinetics of tacrolimus during pregnancy","volume":"34","author":"Zheng","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R47-1-20210211","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/TP.0b013e318278d367","article-title":"Interpreting tacrolimus concentrations during pregnancy and postpartum","volume":"95","author":"Hebert","year":"2013","journal-title":"Transplantation"},{"key":"R48-1-20210211","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/TP.0000000000001342","article-title":"Updated manufacturer and European Medicines Agency recommendations on the use of mycophenolate acid: balancing the risks for male allograft recipients","volume":"100","author":"Kuypers","year":"2016","journal-title":"Transplantation"},{"key":"R49-1-20210211","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Consensus methods for medical and health services research","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"key":"R51-1-20210211","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7182\/pit2013501","article-title":"Patient-reported immunosuppression nonadherence 6 to 24 months after liver transplant: association with pretransplant psychosocial factors and perceptions of health status change","volume":"23","author":"Rodrigue","year":"2013","journal-title":"Prog Transplant"},{"key":"R52-1-20210211","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40620-016-0273-x","article-title":"Nonadherence to immunosuppressive therapy in kidney transplant recipients: can technology help?","volume":"29","author":"Nerini","year":"2016","journal-title":"J Nephrol"},{"key":"R54-1-20210211","doi-asserted-by":"crossref","first-page":"675301","DOI":"10.1155\/2014\/675301","article-title":"Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study","volume":"2014","author":"Tielen","year":"2014","journal-title":"J Transplant"},{"key":"R55-1-20210211","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2215\/CJN.07241009","article-title":"Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation","volume":"5","author":"Prendergast","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R56-1-20210211","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1432-2277.2011.01296.x","article-title":"The spectrum of nonadherence with medication in heart, liver, and lung tranplant patients assessed in various ways","volume":"24","author":"De Bleser","year":"2011","journal-title":"Transpl Int"},{"key":"R57-1-20210211","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/ndt\/gfq376","article-title":"The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies","volume":"26","author":"Tong","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R58-1-20210211","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12160-012-9359-4","article-title":"Non-adherence to immunosuppressive medications in kidney transplantation: intent vs. forgetfulness and clinical markers of medication intake","volume":"44","author":"Griva","year":"2012","journal-title":"Ann Behav Med"},{"key":"R59-1-20210211","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1399-0012.2011.01589.x","article-title":"Factors related to immunosuppressant medication adherence in renal transplant recipients","volume":"26","author":"Chisholm-Burns","year":"2012","journal-title":"Clin Transplant"},{"key":"R60-1-20210211","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1097\/00007890-199812270-00026","article-title":"Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study","volume":"66","author":"Greenstein","year":"1998","journal-title":"Transplantation"},{"key":"R61-1-20210211","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/TP.0000000000000608","article-title":"Discrepancies between beliefs and behavior: a prospective study into immunosuppressive medication adherence after kidney transplantation","volume":"99","author":"Massey","year":"2015","journal-title":"Transplantation"},{"key":"R62-1-20210211","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/01.tp.0000258599.65257.a6","article-title":"Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation","volume":"83","author":"Dew","year":"2007","journal-title":"Transplantation"},{"key":"R63-1-20210211","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1399-0012.2011.01544.x","article-title":"Immunosuppressant treatment adherence, barriers to adherence and quality of life in renal and liver transplant recipients in Spain","volume":"26","author":"Morales","year":"2012","journal-title":"Clin Transplant"},{"key":"R64-1-20210211","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/lt.22294","article-title":"Adherence in liver transplant recipients","volume":"17","author":"Burra","year":"2011","journal-title":"Liver Transpl"},{"key":"R65-1-20210211","first-page":"S89","article-title":"Subclinical nonadherence to immunosuppression: correlates and clinical consequences","volume":"19","author":"De Simone","year":"2013","journal-title":"Liver Transpl"},{"key":"R66-1-20210211","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/tri.12312","article-title":"Describing the evolution of medication nonadherence from pretransplant until 3 years post-transplant and determining pretransplant medication nonadherence as risk factor for post-transplant nonadherence to immunosuppressives: the Swiss Transplant Cohort","volume":"27","author":"De Geest","year":"2014","journal-title":"Transpl Int"},{"key":"R67-1-20210211","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/lt.20828","article-title":"Adherence to medication after liver transplantation in Scotland: a pilot study","volume":"12","author":"O\u2019Carroll","year":"2006","journal-title":"Liver Transpl"},{"key":"R68-1-20210211","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1097\/TP.0b013e3181a440ae","article-title":"Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening","volume":"87","author":"Dobbels","year":"2009","journal-title":"Transplantation"},{"key":"R69-1-20210211","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2165\/00019053-200422180-00006","article-title":"The economic implications of non-adherence after renal transplantation","volume":"22","author":"Cleemput","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"R70-1-20210211","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/jorc.12063","article-title":"Medicine non-adherence in kidney transplantation","volume":"40","author":"Williams","year":"2014","journal-title":"J Ren Care"},{"key":"R71-1-20210211","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/j.1600-6143.2009.02798.x","article-title":"Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression","volume":"9","author":"Pinsky","year":"2009","journal-title":"Am J Transplant"},{"key":"R72-1-20210211","doi-asserted-by":"crossref","first-page":"e0138869","DOI":"10.1371\/journal.pone.0138869","article-title":"Multilevel correlates of non-adherence in kidney transplant patients benefitting from full cost coverage for immunosuppressives: a cross-sectional study","volume":"10","author":"Marsicano","year":"2015","journal-title":"PLoS One"},{"key":"R73-1-20210211","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0193945911434518","article-title":"An ecological perspective on medication adherence","volume":"34","author":"Berben","year":"2012","journal-title":"West J Nurs Res"},{"key":"R74-1-20210211","doi-asserted-by":"crossref","first-page":"e2196","DOI":"10.1097\/MD.0000000000002196","article-title":"Transitional care and adherence of adolescents and young adults after kidney transplantation in Germany and Austria: a binational observatory census within the TRANSNephro trial","volume":"94","author":"Kreuzer","year":"2015","journal-title":"Medicine (Baltimore"},{"key":"R75-1-20210211","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-0012.2009.01056.x","article-title":"Non-adherence to immunosuppressive medication in renal transplant recipients within the scope of the Integrative Model of Behavioral Prediction: a cross-sectional study","volume":"24","author":"Schmid-Mohler","year":"2010","journal-title":"Clin Transplant"},{"key":"R76-1-20210211","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1432-2277.2008.00827.x","article-title":"Medication-taking among adult renal transplant recipients: barriers and strategies","volume":"22","author":"Gordon","year":"2009","journal-title":"Transpl Int"},{"key":"R77-1-20210211","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpsychores.2015.09.001","article-title":"Physician reported adherence to immunosuppressants in renal transplant patients: prevalence, agreement, and correlates","volume":"79","author":"Pabst","year":"2015","journal-title":"J Psychosom Res"},{"key":"R78-1-20210211","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1432-2277.2005.00176.x","article-title":"Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review","volume":"18","author":"Denhaerynck","year":"2005","journal-title":"Transpl Int"},{"key":"R79-1-20210211","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/TP.0b013e3181e346cd","article-title":"The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review","volume":"90","author":"Dobbels","year":"2010","journal-title":"Transplantation"},{"key":"R80-1-20210211","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1600-6143.2007.02127.x","article-title":"Diagnostic accuracy of measurement methods to assess non-adherence to immunosuppressive drugs in kidney transplant recipients","volume":"8","author":"Sch\u00e4fer-Keller","year":"2008","journal-title":"Am J Transplant"},{"key":"R81-1-20210211","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11096-013-9865-x","article-title":"Assessing medication adherence: options to consider","volume":"36","author":"Lehmann","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"R82-1-20210211","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1432-2277.2009.00881.x","article-title":"Interventions to improve medication-adherence after transplantation: a systematic review","volume":"22","author":"De Bleser","year":"2009","journal-title":"Transpl Int"},{"key":"R83-1-20210211","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/PPA.S29549","article-title":"Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions","volume":"7","author":"Hugtenburg","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"R84-1-20210211","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/ctr.12068","article-title":"Evaluation of a collaborative chronic care approach to improve outcomes in kidney transplant recipients","volume":"27","author":"Bissonnette","year":"2013","journal-title":"Clin Transplant"},{"key":"R85-1-20210211","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00007890-201407151-02881","article-title":"Telemedical supported aftercare as an innovative project-study improves the quality of life after living kidney transplantation\u2014a single center experience","volume":"98","author":"Hils","year":"2014","journal-title":"Transplantation"},{"key":"R86-1-20210211","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/152692481102100412","article-title":"Interventions used by health care professionals to enhance medication adherence in transplant patients: a survey of current clinical practice","volume":"21","author":"Berben","year":"2011","journal-title":"Prog Transplant"},{"key":"R87-1-20210211","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/FTD.0000000000000299","article-title":"A prospective randomized trial investigating the influence of pharmaceutical care on the intraindividual variability of tacrolimus concentrations early after kidney transplant","volume":"38","author":"Bessa","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R88-1-20210211","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/ajt.12341","article-title":"Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial","volume":"13","author":"Chisholm-Burns","year":"2013","journal-title":"Am J Transplant"},{"key":"R89-1-20210211","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.healun.2016.01.248","article-title":"Testing the efficacy of a multicomponent theory-based tailored behavioral medication adherence intervention in transplantation: the MAESTRO-TX RCT","volume":"35","author":"Dobbels","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R90-1-20210211","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.ajkd.2016.10.017","article-title":"Automated reminders and physician notification to promote immunosuppression adherence among kidney transplant recipients: a randomized trial","volume":"69","author":"Reese","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R91-1-20210211","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/TP.0000000000000971","article-title":"A prospective randomized trial on the effect of using an electronic monitoring drug dispensing device to improve adherence and compliance","volume":"100","author":"Henriksson","year":"2016","journal-title":"Transplantation"},{"key":"R92-1-20210211","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/jan.12886","article-title":"A compilation of consumers\u2019 stories: the development of a video to enhance medication adherence in newly transplanted kidney recipients","volume":"72","author":"Low","year":"2016","journal-title":"J Adv Nurs"},{"key":"R93-1-20210211","first-page":"98","article-title":"Ten years experience with belatacept-based immunosuppression after kidney transplantation","volume":"6","author":"Grannas","year":"2014","journal-title":"J Clin Med Res"},{"key":"R94-1-20210211","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/TP.0000000000001307","article-title":"Adherence to and acceptance of once-daily tacrolimus after kidney and liver transplant: results from OSIRIS, a French observational study","volume":"100","author":"Cassuto","year":"2016","journal-title":"Transplantation"},{"key":"R95-1-20210211","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e3182725532","article-title":"Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring","volume":"95","author":"Kuypers","year":"2013","journal-title":"Transplantation"},{"key":"R96-1-20210211","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000362792","article-title":"Immunosuppressive medication adherence in kidney transplant patients","volume":"23","author":"Lali\u0107","year":"2014","journal-title":"Med Princ Pract"},{"key":"R97-1-20210211","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5144\/0256-4947.2013.489","article-title":"Optimal management of young adult transplant recipients: the role of integrated multidisciplinary care and peer support","volume":"33","author":"Harden","year":"2013","journal-title":"Ann Saudi Med"},{"key":"R98-1-20210211","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jhep.2011.07.032","article-title":"The adolescent and liver transplantation","volume":"56","author":"Burra","year":"2012","journal-title":"J Hepatol"},{"key":"R99-1-20210211","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1432-2277.2005.00170.x","article-title":"Prevalence of prednisolone (non)compliance in adult liver transplant recipients","volume":"18","author":"Drent","year":"2005","journal-title":"Transpl Int"},{"key":"R100-1-20210211","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1097\/TP.0000000000000639","article-title":"Young adult kidney transplant recipients: nonadherent and happy","volume":"99","author":"Massey","year":"2015","journal-title":"Transplantation"},{"key":"R101-1-20210211","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1600-6143.2006.01360.x","article-title":"Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis","volume":"6","author":"McAlister","year":"2006","journal-title":"Am J Transplant"},{"key":"R102-1-20210211","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"R103-1-20210211","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transplant Rev (Orlando"},{"key":"R104-1-20210211","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.clinthera.2014.02.021","article-title":"Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study","volume":"36","author":"Tsunashima","year":"2014","journal-title":"Clin Ther"},{"key":"R105-1-20210211","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","article-title":"Clinical determinants of calcineurin inhibitor disposition: a mechanistic review","volume":"48","author":"Vanhove","year":"2016","journal-title":"Drug Metab Rev"},{"key":"R106-1-20210211","first-page":"191","article-title":"Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients.","volume":"96","author":"Gaber","year":"2013","journal-title":""},{"key":"R107-1-20210211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2047-1440-3-7","article-title":"A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity","volume":"3","author":"Glick","year":"2014","journal-title":"Transplant Res"},{"key":"R108-1-20210211","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2215\/CJN.03791106","article-title":"Therapeutic monitoring of calcineurin inhibitors for the nephrologist","volume":"2","author":"Schiff","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R109-1-20210211","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R110-1-20210211","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure","volume":"85","author":"Sapir-Pichhadze","year":"2013","journal-title":"Kidney Int"},{"key":"R111-1-20210211","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/tri.12798","article-title":"A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation","volume":"29","author":"Shuker","year":"2016","journal-title":"Transpl Int"},{"key":"R112-1-20210211","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/TP.0000000000001040","article-title":"Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development","volume":"100","author":"Rodrigo","year":"2016","journal-title":"Transplantation"},{"key":"R114-1-20210211","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/lt.24022","article-title":"Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts","volume":"21","author":"Considine","year":"2015","journal-title":"Liver Transpl"},{"key":"R115-1-20210211","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1399-3046.2010.01409.x","article-title":"Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children","volume":"14","author":"Pollock-Barziv","year":"2010","journal-title":"Pediatr Transplant"},{"key":"R116-1-20210211","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jhep.2013.07.032","article-title":"Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors","volume":"59","author":"Barbier","year":"2013","journal-title":"J Hepatol"},{"key":"R117-1-20210211","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2012.09.019","article-title":"Early tacrolimus exposure after liver transplantation: relationship with moderate\/severe acute rejection and long-term outcome","volume":"58","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J Hepatol"},{"key":"R118-1-20210211","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1432-2277.2001.tb00050.x","article-title":"Increased tacrolimus levels during diarrhea","volume":"14","author":"Hochleitner","year":"2001","journal-title":"Transpl Int"},{"key":"R119-1-20210211","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.transproceed.2004.06.026","article-title":"Increased tacrolimus trough levels in association with severe diarrhea, a case report","volume":"36","author":"Asano","year":"2004","journal-title":"Transplant Proc"},{"key":"R120-1-20210211","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/00912700122010519","article-title":"Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R121-1-20210211","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2133\/dmpk.DMPK-13-RG-095","article-title":"Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients","volume":"29","author":"Chen","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"R122-1-20210211","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1208\/s12248-014-9577-8","article-title":"Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach","volume":"16","author":"G\u00e9rard","year":"2014","journal-title":"AAPS J"},{"key":"R123-1-20210211","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/lt.20031","article-title":"Post-liver-transplant anemia: etiology and management","volume":"10","author":"Maheshwari","year":"2004","journal-title":"Liver Transpl"},{"key":"R124-1-20210211","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R125-1-20210211","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/00912700122009999","article-title":"Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R126-1-20210211","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1034\/j.1399-0012.2001.150504.x","article-title":"Effective oral administration of tacrolimus in renal transplant recipients","volume":"15","author":"Kimikawa","year":"2001","journal-title":"Clin Transplant"},{"key":"R127-1-20210211","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/00912700122010104","article-title":"Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R128-1-20210211","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00228-009-0702-z","article-title":"Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study","volume":"6","author":"Liu","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R129-1-20210211","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/157488406776872550","article-title":"Effect of grapefruit juice in relation to human pharmacokinetic study","volume":"1","author":"Uno","year":"2006","journal-title":"Curr Clin Pharmacol"},{"key":"R130-1-20210211","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/01.TP.0000058545.35041.BE","article-title":"Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient","volume":"75","author":"Egashira","year":"2003","journal-title":"Transplantation"},{"key":"R131-1-20210211","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/dmd.32.6.581","article-title":"Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity","volume":"32","author":"Hidaka","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R132-1-20210211","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2133\/dmpk.DMPK-11-RG-105","article-title":"Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats","volume":"27","author":"Egashira","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R133-1-20210211","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00002018-200225100-00003","article-title":"Drug interactions with tacrolimus","volume":"25","author":"van Gelder","year":"2002","journal-title":"Drug Saf"},{"key":"R134-1-20210211","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.3748\/wjg.v19.i48.9156","article-title":"Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients","volume":"19","author":"Provenzani","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R135-1-20210211","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/tpj.2010.42","article-title":"Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective","volume":"11","author":"Li","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"R136-1-20210211","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.0306-5251.2003.01882.x","article-title":"Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids","volume":"56","author":"Hesselink","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R137-1-20210211","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/FTD.0000000000000125","article-title":"Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantation","volume":"37","author":"Lin","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R138-1-20210211","first-page":"11","article-title":"Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring","volume":"13","author":"Kuypers","year":"2008","journal-title":"Ann Transplant"},{"key":"R139-1-20210211","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/tri.12554","article-title":"Mycophenolate revisited","volume":"28","author":"Van Gelder","year":"2015","journal-title":"Transpl Int"},{"key":"R140-1-20210211","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00228-012-1407-2","article-title":"The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers","volume":"69","author":"Tortorici","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R141-1-20210211","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/TP.0b013e3181ccd7f2","article-title":"Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial","volume":"89","author":"Pascual","year":"2010","journal-title":"Transplantation"},{"key":"R142-1-20210211","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients","volume":"30","author":"Dodds-Ashley","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R143-1-20210211","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/ndt\/15.7.1066","article-title":"Interaction between theophylline and tacrolimus in a renal transplant patient","volume":"15","author":"Boubenider","year":"2000","journal-title":"Nephrol Dial Transpl"},{"key":"R144-1-20210211","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1086\/516138","article-title":"Interactions between tacrolimus and antimicrobial agents","volume":"25","author":"Paterson","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R145-1-20210211","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/ajt.12209","article-title":"Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C","volume":"13","author":"Fontana","year":"2013","journal-title":"Am J Transplant"},{"key":"R148-1-20210211","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.dld.2013.08.243","article-title":"Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian Association for the Study of the Liver (AISF)","volume":"46","author":"Coco","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R149-1-20210211","doi-asserted-by":"crossref","first-page":"e000066","DOI":"10.1136\/bmjgast-2015-000066","article-title":"Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis","volume":"3","author":"Nguyen","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"R150-1-20210211","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2005.02502.x","article-title":"Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients","volume":"22","author":"Trotter","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R151-1-20210211","doi-asserted-by":"crossref","first-page":"h3163","DOI":"10.1136\/bmj.h3163","article-title":"Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis","volume":"350","author":"Molnar","year":"2015","journal-title":"BMJ"},{"key":"R152-1-20210211","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/TP.0000000000000384","article-title":"Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed","volume":"99","author":"Robertsen","year":"2015","journal-title":"Transplantation"},{"key":"R153-1-20210211","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ctr.12336","article-title":"Generic tacrolimus in solid organ transplantation","volume":"28","author":"Taube","year":"2014","journal-title":"Clin Transplant"},{"key":"R154-1-20210211","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1432-2277.2011.01378.x","article-title":"ESOT Advisory Committee on Generic Substitution. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs","volume":"24","author":"van Gelder","year":"2011","journal-title":"Transpl Int"},{"key":"R155-1-20210211","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/01.TP.0000437561.31212.0e","article-title":"Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation","volume":"97","author":"Stifft","year":"2014","journal-title":"Transplantation"},{"key":"R156-1-20210211","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/TP.0b013e3182292426","article-title":"Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients","volume":"92","author":"Wu","year":"2011","journal-title":"Transplantation"},{"key":"R157-1-20210211","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ki.2013.484","article-title":"Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation","volume":"85","author":"van Gelder","year":"2014","journal-title":"Kidney Int"},{"key":"R158-1-20210211","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/j.1600-6143.2012.04140.x","article-title":"Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis","volume":"12","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2012","journal-title":"Am J Transplant"},{"key":"R159-1-20210211","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2013.04.003","article-title":"Immunosuppression minimization vs. complete drug withdrawal in liver transplantation","volume":"59","author":"Londo\u00f1o","year":"2013","journal-title":"J Hepatol"},{"key":"R160-1-20210211","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/tri.12570","article-title":"Immunological risks of minimization strategies","volume":"28","author":"Snanoudj","year":"2015","journal-title":"Transpl Int"},{"key":"R161-1-20210211","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1681\/ASN.2010111160","article-title":"Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation","volume":"22","author":"Sharif","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R162-1-20210211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5500\/wjt.v3.i2.7","article-title":"Is it time to give up with calcineurin inhibitors in kidney transplantation?","volume":"3","author":"Salvadori","year":"2013","journal-title":"World J Transplant"},{"key":"R163-1-20210211","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000351648","article-title":"Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence","volume":"37","author":"Issa","year":"2013","journal-title":"Am J Nephrol"},{"key":"R164-1-20210211","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep.26426","article-title":"Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients","volume":"58","author":"Ben\u00edtez","year":"2013","journal-title":"Hepatology"},{"key":"R165-1-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0012.2007.00739.x","article-title":"Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity","volume":"22","author":"Flechner","year":"2008","journal-title":"Clin Transplant"},{"key":"R166-1-20210211","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/j.jhep.2015.02.042","article-title":"From immunosuppression to tolerance","volume":"62","author":"Adams","year":"2015","journal-title":"J Hepatol"},{"key":"R167-1-20210211","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2215\/CJN.03510807","article-title":"Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result","volume":"3","author":"Srinivas","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R168-1-20210211","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/lt.21781","article-title":"Late protocol liver biopsies in the liver allograft: a neglected investigation?","volume":"15","author":"Mells","year":"2009","journal-title":"Liver Transpl"},{"key":"R169-1-20210211","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/lt.23481","article-title":"Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance.","volume":"18","year":"2012","journal-title":"Liver Transpl"},{"key":"R170-1-20210211","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/hep.510280306","article-title":"Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome","volume":"28","author":"Wiesner","year":"1998","journal-title":"Hepatology"},{"key":"R171-1-20210211","first-page":"1152","article-title":"WOFIE hypothesis: some thoughts on an approach toward allograft tolerance","volume":"28","author":"Calne","year":"1996","journal-title":"Transplant Proc"},{"key":"R172-1-20210211","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R173-1-20210211","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"R174-1-20210211","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.trre.2013.06.001","article-title":"Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation","volume":"27","author":"Peddi","year":"2013","journal-title":"Transplant Rev (Orlando"},{"key":"R175-1-20210211","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1600-6143.2011.03505.x","article-title":"Chronic progressive calcineurin nephrotoxicity: an overstated concept","volume":"11","author":"Matas","year":"2011","journal-title":"Am J Transplant"},{"key":"R176-1-20210211","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R177-1-20210211","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am J Transplant"},{"key":"R178-1-20210211","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/ajt.13182","article-title":"Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens\u2014the DIAMOND study","volume":"15","author":"Trunecka","year":"2015","journal-title":"Am J Transplant"},{"key":"R179-1-20210211","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"key":"R180-1-20210211","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients","volume":"100","author":"O'Leary","year":"2016","journal-title":"Transplantation"},{"key":"R181-1-20210211","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/ajt.13476","article-title":"Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts","volume":"16","author":"O\u2019Leary","year":"2016","journal-title":"Am J Transplant"},{"key":"R182-1-20210211","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.transproceed.2007.02.030","article-title":"Liver transplantation for autoimmune hepatitis: a single-center experience","volume":"39","author":"Khalaf","year":"2007","journal-title":"Transplant Proc"},{"key":"R183-1-20210211","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/ctr.12691","article-title":"Repeat liver retransplantation: rationale and outcomes","volume":"30","author":"Memeo","year":"2016","journal-title":"Clin Transplant"},{"key":"R184-1-20210211","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4254\/wjh.v7.i10.1355","article-title":"Review on immunosuppression in liver transplantation","volume":"7","author":"Moini","year":"2015","journal-title":"World J Hepatol"},{"key":"R185-1-20210211","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.3748\/wjg.v20.i32.11095","article-title":"Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem","volume":"20","author":"Grassi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R186-1-20210211","doi-asserted-by":"crossref","first-page":"707","DOI":"10.12659\/AOT.895320","article-title":"Long-term renal function in liver transplant recipients after conversion from calcineurin inhibitors to mTOR inhibitors","volume":"20","author":"H\u00fcsing","year":"2015","journal-title":"Ann Transplant"},{"key":"R187-1-20210211","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1478-3231.2011.02563.x","article-title":"Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation","volume":"32","author":"Saner","year":"2012","journal-title":"Liver Int"},{"key":"R188-1-20210211","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trre.2016.02.002","article-title":"Immunological risk assessment: the key to individualized immunosuppression after kidney transplantation","volume":"30","author":"Pratschke","year":"2016","journal-title":"Transplant Rev (Orlando"},{"key":"R189-1-20210211","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/TP.0000000000000650","article-title":"Immunosuppression modifications based on an immune response assay: results of a randomized, controlled trial","volume":"99","author":"Ravaioli","year":"2015","journal-title":"Transplantation"},{"key":"R190-1-20210211","first-page":"177","article-title":"Immunosuppression in kidney transplantation","volume":"86","author":"Muntean","year":"2013","journal-title":"Clujul Med"},{"key":"R191-1-20210211","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ki.2015.268","article-title":"Finding the safe place between the hammer and the anvil: sounding the depth of therapeutic immunosuppression","volume":"88","author":"Thaunat","year":"2015","journal-title":"Kidney Int"},{"key":"R192-1-20210211","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lt.22410","article-title":"Present state of immunosuppressive therapy in liver transplant recipients","volume":"17","author":"Wiesner","year":"2011","journal-title":"Liver Transpl"},{"key":"R193-1-20210211","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/clpt.2011.111","article-title":"Biomarkers of over-immunosuppression","volume":"90","author":"Budde","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R194-1-20210211","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/17425255.2011.544249","article-title":"Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions","volume":"7","author":"Christians","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R195-1-20210211","doi-asserted-by":"crossref","first-page":"a015669","DOI":"10.1101\/cshperspect.a015669","article-title":"Opportunistic infections\u2014coming to the limits of immunosuppression?","volume":"3","author":"Fishman","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R196-1-20210211","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1600-6143.2010.03181.x","article-title":"Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit","volume":"10","author":"Collett","year":"2010","journal-title":"Am J Transplant"},{"key":"R197-1-20210211","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/tri.12165","article-title":"Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients","volume":"26","author":"Wimmer","year":"2013","journal-title":"Transpl Int"},{"key":"R198-1-20210211","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1111\/j.1600-6143.2012.04192.x","article-title":"Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection","volume":"12","author":"Fern\u00e1ndez-Ruiz","year":"2012","journal-title":"Am J Transplant"},{"key":"R199-1-20210211","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/ajt.12055","article-title":"Hypocomplementemia in kidney transplant recipients: impact on the risk of infectious complications","volume":"13","author":"Fern\u00e1ndez-Ruiz","year":"2013","journal-title":"Am J Transplant"},{"key":"R200-1-20210211","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/TP.0b013e3181ac8e36","article-title":"Low serum mannose-binding lectin as a risk factor for new onset diabetes mellitus after renal transplantation","volume":"88","author":"Ibernon","year":"2009","journal-title":"Transplantation"},{"key":"R201-1-20210211","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/tri.12321","article-title":"Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation","volume":"27","author":"Fern\u00e1ndez-Ruiz","year":"2014","journal-title":"Transpl Int"},{"key":"R202-1-20210211","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1038\/cti.2014.3","article-title":"Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation","volume":"3","author":"Fern\u00e1ndez-Ruiz","year":"2014","journal-title":"Clin Transl Immunol"},{"key":"R203-1-20210211","first-page":"737","article-title":"Can immune cell function assay identify patients at risk of infection or rejection?","volume":"93","author":"Ling","year":"2012","journal-title":"A meta-analysis. Transplantation"},{"key":"R204-1-20210211","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ndt\/gfu023","article-title":"BK virus infection: an update on diagnosis and treatment","volume":"30","author":"Sawinski","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R205-1-20210211","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"key":"R206-1-20210211","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"R207-1-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajt.12002","article-title":"Overview: cytomegalovirus and the herpesviruses in transplantation","volume":"13","author":"Fishman","year":"2013","journal-title":"Am J Transplant"},{"key":"R208-1-20210211","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"R209-1-20210211","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/01.TP.0000173822.05877.D7","article-title":"Influence of age in renal transplant infections: cases and controls study","volume":"80","author":"Trouillhet","year":"2005","journal-title":"Transplantation"},{"key":"R210-1-20210211","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1523-1755.2003.00103.x","article-title":"Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy","volume":"64","author":"Buehrig","year":"2003","journal-title":"Kidney Int"},{"key":"R211-1-20210211","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ajt.12110","article-title":"BK polyomavirus in solid organ transplantation","volume":"13","author":"Hirsch","year":"2013","journal-title":"Am J Transplant"},{"key":"R213-1-20210211","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/tid.12489","article-title":"Serial testing for latent tuberculosis infection in transplant candidates: a retrospective review","volume":"18","author":"Roth","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"R214-1-20210211","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1097\/TP.0000000000001224","article-title":"Prevention and management of tuberculosis in transplant recipients: from guidelines to clinical practice","volume":"100","author":"Mu\u00f1oz","year":"2016","journal-title":"Transplantation"},{"key":"R215-1-20210211","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0b013e31824810e6","article-title":"Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients","volume":"93","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"R216-1-20210211","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/TP.0b013e3182708e56","article-title":"Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis","volume":"94","author":"Andrassy","year":"2012","journal-title":"Transplantation"},{"key":"R217-1-20210211","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am J Transplant"},{"key":"R218-1-20210211","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/tid.12494","article-title":"Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid","volume":"18","author":"Radtke","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R219-1-20210211","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/ajt.13541","article-title":"BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12","volume":"16","author":"Hirsch","year":"2016","journal-title":"Am J Transplant"},{"key":"R220-1-20210211","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ki.2013.538","article-title":"The immune phenotype may relate to cancer development in kidney transplant recipients","volume":"86","author":"Hope","year":"2014","journal-title":"Kidney Int"},{"key":"R221-1-20210211","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.2215\/CJN.03320807","article-title":"Cancer screening in renal transplant recipients: what is the evidence?","volume":"3","author":"Wong","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R222-1-20210211","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/ndt\/gfs523","article-title":"Colorectal cancer screening in kidney disease patients: working backwards","volume":"28","author":"Kiberd","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R223-1-20210211","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1111\/j.1600-6143.2012.04248.x","article-title":"De novo kidney graft tumors: results from a multicentric retrospective national study","volume":"12","author":"Tillou","year":"2012","journal-title":"Am J Transplant"},{"key":"R224-1-20210211","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi\u2019s sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"R225-1-20210211","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"key":"R226-1-20210211","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer","volume":"12","author":"Campbell","year":"2012","journal-title":"Am J Transplant"},{"key":"R227-1-20210211","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2012.45.6376","article-title":"Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus","volume":"31","author":"Hoogendijk-van den Akker","year":"2013","journal-title":"J Clin Oncol"},{"key":"R228-1-20210211","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R229-1-20210211","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fmb.12.28","article-title":"Invasive fungal infections in solid organ transplant recipients","volume":"7","author":"Shoham","year":"2012","journal-title":"Future Microbiol"},{"key":"R230-1-20210211","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/lt.23467","article-title":"Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003\u20132007)","volume":"18","author":"Raghuram","year":"2012","journal-title":"Liver Transpl"},{"key":"R231-1-20210211","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.3748\/wjg.v20.i31.10658","article-title":"Cytomegalovirus infection in liver transplant recipients: updates on clinical management","volume":"20","author":"Marcelin","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R232-1-20210211","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/j.1600-6143.2008.02369.x","article-title":"Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review","volume":"8","author":"Sun","year":"2008","journal-title":"Am J Transplant"},{"key":"R233-1-20210211","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12594","article-title":"Cytomegalovirus infection in solid organ transplant recipients","volume":"20","author":"Lumbreras","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R234-1-20210211","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1478-3231.2009.02085.x","article-title":"Current management of hepatitis B virus infection before and after liver transplantation","volume":"29","author":"Papatheodoridis","year":"2009","journal-title":"Liver Int"},{"key":"R235-1-20210211","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-2004-828679","article-title":"Management of hepatitis B in liver transplantation patients","volume":"24","author":"Samuel","year":"2004","journal-title":"Semin Liver Dis"},{"key":"R236-1-20210211","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","article-title":"Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation","volume":"141","author":"Fung","year":"2011","journal-title":"Gastroenterology"},{"key":"R237-1-20210211","first-page":"23","article-title":"Treatment of hepatitis C virus infection in liver transplant recipients","volume":"12","author":"Suraweera","year":"2016","journal-title":"Gastroenterol Hepatol (N Y"},{"key":"R238-1-20210211","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL Clinical Practice Guidelines: Liver transplantation.","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R239-1-20210211","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1478-3231.2010.02303.x","article-title":"Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review","volume":"30","author":"Chak","year":"2010","journal-title":"Liver Int"},{"key":"R240-1-20210211","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1432-2277.2012.01562.x","article-title":"Recurrent hepatocellular carcinoma after liver transplantation\u2014an emerging clinical challenge","volume":"26","author":"Welker","year":"2013","journal-title":"Transpl Int"},{"key":"R241-1-20210211","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/lt.22064","article-title":"Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age","volume":"16","author":"Tjon","year":"2010","journal-title":"Liver Transpl"},{"key":"R242-1-20210211","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J Hepatol"},{"key":"R243-1-20210211","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4254\/wjh.v6.i11.776","article-title":"Mammalian target of rapamycin inhibition in hepatocellular carcinoma","volume":"6","author":"Ashworth","year":"2014","journal-title":"World J Hepatol"},{"key":"R244-1-20210211","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"R245-1-20210211","doi-asserted-by":"crossref","first-page":"8753","DOI":"10.3748\/wjg.v21.i29.8753","article-title":"Neoplastic disease after liver transplantation: focus on de novo neoplasms","volume":"21","author":"Burra","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R246-1-20210211","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"key":"R247-1-20210211","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/jlts.2002.32977","article-title":"Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation","volume":"8","author":"Saigal","year":"2002","journal-title":"Liver Transpl"},{"key":"R248-1-20210211","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"R249-1-20210211","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0000000000000555","article-title":"Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study","volume":"99","author":"Fischer","year":"2015","journal-title":"Transplantation"},{"key":"R250-1-20210211","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/ajt.12280","article-title":"Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study","volume":"13","author":"Saliba","year":"2013","journal-title":"Am J Transplant"},{"key":"R251-1-20210211","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/lt.20903","article-title":"Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation","volume":"12","author":"Pageaux","year":"2006","journal-title":"Liver Transpl"},{"key":"R252-1-20210211","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1373\/clinchem.2015.243030","article-title":"Performance of cystatin C- and creatinine-based estimated glomerular filtration rate equations depends on patient characteristics","volume":"61","author":"Meeusen","year":"2015","journal-title":"Clin Chem"},{"key":"R253-1-20210211","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation\u2014PROTECT","volume":"12","author":"Fischer","year":"2012","journal-title":"Am J Transplant"},{"key":"R254-1-20210211","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/lt.21116","article-title":"Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients","volume":"13","author":"Morard","year":"2007","journal-title":"Liver Transpl"},{"key":"R255-1-20210211","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jhep.2011.06.013","article-title":"Sirolimus\u2014it doesn\u2019t deserve its bad Rap(a)","volume":"56","author":"McKenna","year":"2012","journal-title":"J Hepatol"},{"key":"R256-1-20210211","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrneph.2012.81","article-title":"The impact of donor-specific anti-HLA antibodies on late kidney allograft failure","volume":"8","author":"Loupy","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"R257-1-20210211","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"R258-1-20210211","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med"},{"key":"R259-1-20210211","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1681\/ASN.2013101144","article-title":"Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss","volume":"26","author":"Sicard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R260-1-20210211","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2014111120","article-title":"IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury","volume":"27","author":"Lefaucheur","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R261-1-20210211","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/TP.0b013e31825d1587","article-title":"The treatment of acute antibody-mediated rejection in kidney transplant recipients\u2014a systematic review","volume":"94","author":"Roberts","year":"2012","journal-title":"Transplantation"},{"key":"R263-1-20210211","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.humimm.2016.02.006","article-title":"Donor-specific antibodies and liver transplantation","volume":"77","author":"Del Bello","year":"2016","journal-title":"Hum Immunol"},{"key":"R264-1-20210211","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/MOT.0b013e328353584c","article-title":"Antibody-mediated rejection in the liver allograft","volume":"17","author":"H\u00fcbscher","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"R265-1-20210211","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts","volume":"95","author":"Everly","year":"2013","journal-title":"Transplantation"},{"key":"R266-1-20210211","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1111\/ajt.12365","article-title":"Rejection: an integrated response","volume":"13","author":"Nickerson","year":"2013","journal-title":"Am J Transplant"},{"key":"R267-1-20210211","doi-asserted-by":"crossref","first-page":"890","DOI":"10.5301\/jn.5000207","article-title":"Renal transplant allocation criteria, desensitization strategies and immunosuppressive therapy in retransplant renal patients","volume":"25","author":"Salvadori","year":"2012","journal-title":"J Nephrol"},{"key":"R268-1-20210211","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/ndt\/gfu208","article-title":"Pregnancy after kidney transplantation: outcome and anti-human leucocyte antigen alloimmunization risk","volume":"29","author":"Hebral","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R269-1-20210211","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2165\/11631110-000000000-00000","article-title":"Identification and therapeutic management of highly sensitized patients undergoing renal transplantation","volume":"72","author":"Huber","year":"2012","journal-title":"Drugs"},{"key":"R270-1-20210211","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/ajt.13132","article-title":"Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA","volume":"15","author":"Rostaing","year":"2015","journal-title":"Am J Transplant"},{"key":"R271-1-20210211","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"R272-1-20210211","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/TP.0000000000001268","article-title":"Belatacept: a game changer?","volume":"100","author":"Van Gelder","year":"2016","journal-title":"Transplantation"},{"key":"R273-1-20210211","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/TP.0b013e31817fdddb","article-title":"Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant","volume":"86","author":"Opelz","year":"2008","journal-title":"Transplantation"},{"key":"R274-1-20210211","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"},{"key":"R275-1-20210211","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MOT.0000000000000194","article-title":"ABO-compatible liver allograft antibody-mediated rejection: an update","volume":"20","author":"Demetris","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"R276-1-20210211","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transplant"},{"key":"R277-1-20210211","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/lt.23707","article-title":"Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation","volume":"19","author":"Musat","year":"2013","journal-title":"Liver Transpl"},{"key":"R278-1-20210211","doi-asserted-by":"crossref","first-page":"972705","DOI":"10.1155\/2013\/972705","article-title":"Significance of semiquantitative assessment of preformed donor-specific antibody using luminex single bead assay in living related liver transplantation","volume":"2013","author":"Yoshizawa","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"R279-1-20210211","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/lt.23687","article-title":"Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation","volume":"19","author":"O\u2019Leary","year":"2013","journal-title":"Liver Transpl"},{"key":"R280-1-20210211","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/lt.23854","article-title":"Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients","volume":"20","author":"O\u2019Leary","year":"2014","journal-title":"Liver Transpl"},{"key":"R281-1-20210211","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/lt.21981","article-title":"Human leukocyte antigen crossmatch testing is important for liver retransplantation","volume":"16","author":"Goh","year":"2010","journal-title":"Liver Transpl"},{"key":"R282-1-20210211","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1111\/j.1600-6143.2012.03995.x","article-title":"Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year","volume":"12","author":"Taner","year":"2012","journal-title":"Am J Transplant"},{"key":"R283-1-20210211","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/lt.22233","article-title":"Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies","volume":"17","author":"Kozlowski","year":"2011","journal-title":"Liver Transpl"},{"key":"R284-1-20210211","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/TP.0b013e3182a688c0","article-title":"Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction","volume":"97","author":"Kubal","year":"2014","journal-title":"Transplantation"},{"key":"R285-1-20210211","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/ajt.13153","article-title":"Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation","volume":"15","author":"O\u2019Leary","year":"2015","journal-title":"Am J Transplant"},{"key":"R286-1-20210211","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1600-6143.2011.03593.x","article-title":"High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection post-liver transplant","volume":"11","author":"O\u2019Leary","year":"2011","journal-title":"Am J Transplant"},{"key":"R287-1-20210211","doi-asserted-by":"crossref","first-page":"e0131237","DOI":"10.1371\/journal.pone.0131237","article-title":"Prevalence and predictors of early cardiovascular events after kidney transplantation: evaluation of pre-transplant cardiovascular work-up","volume":"10","author":"Delville","year":"2015","journal-title":"PLoS One"},{"key":"R288-1-20210211","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/lt.22468","article-title":"Cumulative risk of cardiovascular events after orthotopic liver transplantation","volume":"18","author":"Albeldawi","year":"2012","journal-title":"Liver Transpl"},{"key":"R289-1-20210211","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.trre.2013.12.001","article-title":"Cardiovascular complications after transplantation: treatment options in solid organ recipients","volume":"28","author":"Gillis","year":"2014","journal-title":"Transplant Rev (Orlando"},{"key":"R291-1-20210211","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/lt.23508","article-title":"Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies","volume":"18","author":"Madhwal","year":"2012","journal-title":"Liver Transpl"},{"key":"R292-1-20210211","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/tri.12413","article-title":"Cardiovascular morbidity and mortality after kidney transplantation","volume":"28","author":"Stoumpos","year":"2015","journal-title":"Transpl Int"},{"key":"R293-1-20210211","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2010.01.040","article-title":"Metabolic syndrome and liver transplantation: a review and guide to management","volume":"53","author":"Watt","year":"2010","journal-title":"J Hepatol"},{"key":"R294-1-20210211","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000334158","article-title":"Long-term management of the kidney transplant recipient","volume":"33","author":"Schaefer","year":"2012","journal-title":"Blood Purif"},{"key":"R295-1-20210211","doi-asserted-by":"crossref","first-page":"iii47","DOI":"10.1093\/ndt\/gfh1015","article-title":"Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation","volume":"19","author":"Fern\u00e1ndez-Fresnedo","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R296-1-20210211","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transplant"},{"key":"R297-1-20210211","first-page":"643","article-title":"Incidence and risk factors for diabetes, hypertension and obesity after liver transplantation","volume":"28","author":"Anast\u00e1cio","year":"2013","journal-title":"Nutr Hosp"},{"key":"R298-1-20210211","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/gutjnl-2011-300886","article-title":"Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis","volume":"61","author":"Newsome","year":"2012","journal-title":"Gut"},{"key":"R299-1-20210211","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.mayocp.2012.02.021","article-title":"Long-term medical management of the liver transplant recipient: what the primary care physician needs to know","volume":"87","author":"Singh","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"R300-1-20210211","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrgastro.2015.172","article-title":"Keys to long-term care of the liver transplant recipient","volume":"12","author":"Watt","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R302-1-20210211","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/tri.12218","article-title":"Death within the first year after kidney transplantation\u2014an observational cohort study","volume":"27","author":"Farrugia","year":"2014","journal-title":"Transpl Int"},{"key":"R303-1-20210211","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jacc.2012.05.008","article-title":"Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"60","author":"Lentine","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R304-1-20210211","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/lt.23950","article-title":"High early cardiovascular mortality after liver transplantation","volume":"20","author":"Van Wagner","year":"2014","journal-title":"Liver Transpl"},{"key":"R305-1-20210211","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/ajt.13779","article-title":"Factors associated with major adverse cardiovascular events after liver transplantation among a national sample","volume":"16","author":"Van Wagner","year":"2016","journal-title":"Am J Transplant"},{"key":"R306-1-20210211","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ajt.13034","article-title":"Postoperative atrial fibrillation in liver transplantation","volume":"15","author":"Xia","year":"2015","journal-title":"Am J Transplant"},{"key":"R307-1-20210211","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/lt.24137","article-title":"Cardiovascular disease after liver transplantation: when, what, and who is at risk","volume":"21","author":"Fussner","year":"2015","journal-title":"Liver Transpl"},{"key":"R308-1-20210211","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/ctr.12520","article-title":"Cardiovascular risk and events after liver transplantation. Experiences from 313 consecutive transplants with a follow-up of 20 years","volume":"29","author":"Schoening","year":"2015","journal-title":"Clin Transplant"},{"key":"R309-1-20210211","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.transproceed.2012.06.022","article-title":"Metabolic syndrome and cardiovascular risk after liver transplantation: a single-center experience","volume":"44","author":"Iadevaia","year":"2012","journal-title":"Transplant Proc"},{"key":"R310-1-20210211","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/DMSO.S19027","article-title":"New onset diabetes after transplantation (NODAT): an overview","volume":"4","author":"Pham","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R311-1-20210211","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MOT.0b013e32832dbb98","article-title":"New-onset diabetes after transplantation: a review of recent literature","volume":"14","author":"Balla","year":"2009","journal-title":"Curr Opin Organ Transplant"},{"key":"R312-1-20210211","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.transproceed.2011.03.019","article-title":"Metabolic syndrome and cardiovascular disease in kidney transplantation","volume":"43","author":"Salerno","year":"2011","journal-title":"Transplant Proc"},{"key":"R313-1-20210211","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-6143.2009.02949.x","article-title":"Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study","volume":"10","author":"Israni","year":"2010","journal-title":"Am J Transplant"},{"key":"R314-1-20210211","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.transproceed.2015.03.031","article-title":"Metabolic profile and cardiovascular risk in a population of renal transplant recipients","volume":"47","author":"Gon\u00e7alves","year":"2015","journal-title":"Transplant Proc"},{"key":"R315-1-20210211","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant"},{"key":"R316-1-20210211","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.transproceed.2012.04.039","article-title":"A retrospective study of the Framingham cardiovascular risk scores in a liver transplant population","volume":"45","author":"Mansell","year":"2013","journal-title":"Transplant Proc"},{"key":"R317-1-20210211","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1111\/j.1523-1755.2005.00349.x","article-title":"New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation","volume":"67","author":"Cosio","year":"2005","journal-title":"Kidney Int"},{"key":"R318-1-20210211","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/TP.0b013e3182584831","article-title":"Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation","volume":"94","author":"Wauters","year":"2012","journal-title":"Transplantation"},{"key":"R319-1-20210211","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1681\/ASN.V1341084","article-title":"Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease","volume":"13","author":"Rigatto","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R320-1-20210211","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1681\/ASN.V71158","article-title":"Cardiovascular disease after renal transplantation","volume":"7","author":"Kasiske","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R321-1-20210211","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1111\/j.1600-6143.2005.00983.x","article-title":"Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation","volume":"5","author":"Fellstr\u00f6m","year":"2005","journal-title":"Am J Transplant"},{"key":"R322-1-20210211","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/TP.0b013e31825f0f97","article-title":"Diastolic dysfunction in patients with end-stage liver disease is associated with development of heart failure early after liver transplantation","volume":"94","author":"Dowsley","year":"2012","journal-title":"Transplantation"},{"key":"R323-1-20210211","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/lt.24060","article-title":"Preexisting atrial fibrillation and cardiac complications after liver transplantation","volume":"21","author":"Bargehr","year":"2015","journal-title":"Liver Transpl"},{"key":"R324-1-20210211","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.TP.0000442781.31885.a2","article-title":"Pre-transplant renal impairment predicts posttransplant cardiac events in patients with liver cirrhosis","volume":"98","author":"Josefsson","year":"2014","journal-title":"Transplantation"},{"key":"R325-1-20210211","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2459\/JCM.0000000000000207","article-title":"The impact of coronary artery disease on outcomes after liver transplantation","volume":"17","author":"Skaro","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown"},{"key":"R326-1-20210211","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/bja\/aeu384","article-title":"Preoperative coronary calcium score is predictive of early postoperative cardiovascular complications in liver transplant recipients","volume":"114","author":"Kong","year":"2015","journal-title":"Br J Anaesth"},{"key":"R327-1-20210211","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/lt.23818","article-title":"Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation","volume":"20","author":"Dare","year":"2014","journal-title":"Liver Transpl"},{"key":"R328-1-20210211","doi-asserted-by":"crossref","first-page":"8667","DOI":"10.3748\/wjg.v20.i26.8667","article-title":"Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation","volume":"20","author":"Alvares-da-Silva","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R329-1-20210211","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/lt.23880","article-title":"Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events","volume":"20","author":"Watt","year":"2014","journal-title":"Liver Transpl"},{"key":"R330-1-20210211","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1600-6143.2012.04077.x","article-title":"Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation","volume":"12","author":"Parekh","year":"2012","journal-title":"Am J Transplant"},{"key":"R331-1-20210211","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/liv.12872","article-title":"Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis","volume":"35","author":"Van Wagner","year":"2015","journal-title":"Liver Int"},{"key":"R332-1-20210211","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.25855","article-title":"Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events","volume":"56","author":"Van Wagner","year":"2012","journal-title":"Hepatology"},{"key":"R333-1-20210211","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"R334-1-20210211","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/lt.500050406","article-title":"Improved physical performance after orthotopic liver transplantation","volume":"5","author":"Beyer","year":"1999","journal-title":"Liver Transpl Surg"},{"key":"R335-1-20210211","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/jlts.2001.22184","article-title":"Physical activity and health-related quality of life in liver transplant recipients","volume":"7","author":"Painter","year":"2001","journal-title":"Liver Transpl"},{"key":"R336-1-20210211","first-page":"259","article-title":"KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease.","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"R337-1-20210211","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1590\/S1020-49892012001000008","article-title":"Reducing salt intake to prevent hypertension and cardiovascular disease","volume":"32","author":"He","year":"2012","journal-title":"Rev Panam Salud Publica"},{"key":"R338-1-20210211","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.transproceed.2013.08.067","article-title":"Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants?","volume":"45","author":"Choi","year":"2013","journal-title":"Transplant Proc"},{"key":"R339-1-20210211","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2337\/dc11-1230","article-title":"New-onset diabetes after renal transplantation: risk assessment and management","volume":"35","author":"Ghisdal","year":"2012","journal-title":"Diabetes Care"},{"key":"R340-1-20210211","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"key":"R341-1-20210211","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"R342-1-20210211","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1681\/ASN.2011080835","article-title":"Early basal insulin therapy decreases new-onset diabetes after renal transplantation","volume":"23","author":"Hecking","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R343-1-20210211","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/ajt.12518","article-title":"Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation\u2014a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Haidinger","year":"2014","journal-title":"Am J Transplant"},{"key":"R344-1-20210211","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"R345-1-20210211","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"R346-1-20210211","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/j.1600-6143.2012.04084.x","article-title":"Dyslipidemia and its therapeutic challenges in renal transplantation","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"R347-1-20210211","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1111\/j.1600-6143.2005.01093.x","article-title":"Improved long-term outcomes after renal transplantation associated with blood pressure control","volume":"5","author":"Opelz","year":"2005","journal-title":"Am J Transplant"},{"key":"R348-1-20210211","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ndt\/gfp581","article-title":"Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET","volume":"25","author":"Philipp","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R349-1-20210211","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S2213-8587(15)00368-X","article-title":"Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial","volume":"4","author":"Knoll","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R350-1-20210211","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/j.1600-6143.2007.01928.x","article-title":"Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence","volume":"7","author":"Hiremath","year":"2007","journal-title":"Am J Transpl"},{"key":"R351-1-20210211","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/01.TP.0000437672.78716.28","article-title":"Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers","volume":"97","author":"Opelz","year":"2014","journal-title":"Transplantation"},{"key":"R352-1-20210211","first-page":"ii32","article-title":"Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study","volume":"3","author":"Gonzalez-Molina","year":"2010","journal-title":"NDT Plus"},{"key":"R353-1-20210211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"19","author":"Lucey","year":"2013","journal-title":"Liver Transpl"},{"key":"R354-1-20210211","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1600-6143.2012.04318.x","article-title":"Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease","volume":"13","author":"Heimbach","year":"2013","journal-title":"Am J Transplant"},{"key":"R355-1-20210211","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/MCG.0000000000000396","article-title":"Endoscopic bypass using endobarrier devices: efficacy in treating obesity and metabolic syndrome","volume":"49","author":"Jain","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"R356-1-20210211","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.soard.2016.02.006","article-title":"Endoscopic treatments of obesity: a comprehensive review","volume":"12","author":"Neylan","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"R357-1-20210211","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/01.ASN.0000071515.27754.67","article-title":"Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus","volume":"14","author":"Artz","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R358-1-20210211","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/ajt.12460","article-title":"Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study","volume":"13","author":"Rostaing","year":"2013","journal-title":"Am J Transplant"},{"key":"R359-1-20210211","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/TP.0b013e31827722c9","article-title":"The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials","volume":"95","author":"Soveri","year":"2013","journal-title":"Transplantation"},{"key":"R360-1-20210211","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/ctr.12557","article-title":"Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients","volume":"29","author":"Cuervas-Mons","year":"2015","journal-title":"Clin Transplant"},{"key":"R361-1-20210211","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.transproceed.2014.11.036","article-title":"Incidence of cardiovascular and cerebrovascular events associated with sirolimus use after liver transplantation","volume":"47","author":"Weick","year":"2015","journal-title":"Transplant Proc"},{"key":"R362-1-20210211","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(11)61334-2","article-title":"Prevention of cardiovascular disease in adult recipients of kidney transplants","volume":"378","author":"Jardine","year":"2011","journal-title":"Lancet"},{"key":"R363-1-20210211","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/ndt\/gfn667","article-title":"Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis","volume":"24","author":"Yarlagadda","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R364-1-20210211","doi-asserted-by":"crossref","first-page":"e0144188","DOI":"10.1371\/journal.pone.0144188","article-title":"Prolonged delayed graft function is associated with inferior patient and kidney allograft survivals","volume":"10","author":"de Sandes-Freitas","year":"2015","journal-title":"PLoS One"},{"key":"R365-1-20210211","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/tri.12712","article-title":"Optimized donor management and organ preservation before kidney transplantation","volume":"29","author":"Mundt","year":"2016","journal-title":"Transpl Int"},{"key":"R366-1-20210211","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.2009.1310","article-title":"Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial","volume":"302","author":"Schnuelle","year":"2009","journal-title":"JAMA"},{"key":"R367-1-20210211","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJMoa1501969","article-title":"Therapeutic hypothermia in deceased organ donors and kidney-graft function","volume":"373","author":"Niemann","year":"2015","journal-title":"N Engl J Med"},{"key":"R368-1-20210211","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/bjs.9169","article-title":"Systematic review and meta-analysis of hypothermic machine perfusion versus static cold storage of kidney allografts on transplant outcomes","volume":"100","author":"O\u2019Callaghan","year":"2013","journal-title":"Br J Surg"},{"key":"R369-1-20210211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMoa0802289","article-title":"Machine perfusion or cold storage in deceased-donor kidney transplantation","volume":"360","author":"Moers","year":"2009","journal-title":"N Engl J Med"},{"key":"R370-1-20210211","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.juro.2012.11.173","article-title":"Renal perfusion pump vs cold storage for donation after cardiac death kidneys: a systematic review","volume":"189","author":"Bathini","year":"2013","journal-title":"J Urol"},{"key":"R371-1-20210211","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/tri.12319","article-title":"Normothermic machine perfusion of the kidney: better conditioning and repair?","volume":"28","author":"Hosgood","year":"2015","journal-title":"Transpl Int"},{"key":"R372-1-20210211","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.ajkd.2012.11.050","article-title":"Delayed graft function after kidney transplantation: the clinical perspective","volume":"62","author":"Sharif","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R373-1-20210211","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/01.TP.0000045683.85282.93","article-title":"Aggressive pharmacologic donor management results in more transplanted organs","volume":"75","author":"Rosendale","year":"2003","journal-title":"Transplantation"},{"key":"R375-1-20210211","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.gastrohep.2010.05.008","article-title":"Current management of biliary complications after liver transplantation: emphasis on endoscopic therapy","volume":"34","author":"Balderramo","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"R376-1-20210211","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/lt.23985","article-title":"Early allograft dysfunction in liver transplantation using donation after cardiac death donors results in inferior survival","volume":"20","author":"Lee","year":"2014","journal-title":"Liver Transpl"},{"key":"R377-1-20210211","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/lt.22091","article-title":"Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors","volume":"16","author":"Olthoff","year":"2010","journal-title":"Liver Transpl"},{"key":"R378-1-20210211","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4253\/wjge.v7.i6.606","article-title":"Endoscopic management of biliary complications after liver transplantation: an evidence-based review","volume":"7","author":"Mac\u00edas-G\u00f3mez","year":"2015","journal-title":"World J Gastrointest Endosc"},{"key":"R379-1-20210211","doi-asserted-by":"crossref","first-page":"145","DOI":"10.12659\/AOT.896190","article-title":"Impact of cold ischemia time on outcomes of liver transplantation: a single center experience","volume":"21","author":"Sibulesky","year":"2016","journal-title":"Ann Transplant"},{"key":"R380-1-20210211","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5604\/16652681.1184212","article-title":"Early allograft dysfunction after liver transplantation: an intermediate outcome measure for targeted improvements","volume":"15","author":"Lee","year":"2016","journal-title":"Ann Hepatol"},{"key":"R381-1-20210211","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/jlts.2003.50015","article-title":"Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion","volume":"9","author":"Moench","year":"2003","journal-title":"Liver Transpl"},{"key":"R382-1-20210211","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/lt.21509","article-title":"Biliary strictures following liver transplantation: past, present and preventive strategies","volume":"14","author":"Sharma","year":"2008","journal-title":"Liver Transpl"},{"key":"R383-1-20210211","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1432-2277.2010.01150.x","article-title":"How important is the duration of the brain death period for the outcome in kidney transplantation?","volume":"24","author":"Nijboer","year":"2011","journal-title":"Transpl Int"},{"key":"R384-1-20210211","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/SLA.0b013e318190e70c","article-title":"Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial","volume":"248","author":"Kotsch","year":"2008","journal-title":"Ann Surg"},{"key":"R385-1-20210211","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/lt.23527","article-title":"Use of N -acetylcysteine during liver procurement: a prospective randomized controlled study","volume":"19","author":"D\u2019Amico","year":"2013","journal-title":"Liver Transpl"},{"key":"R386-1-20210211","doi-asserted-by":"crossref","first-page":"436145","DOI":"10.1155\/2010\/436145","article-title":"Release of danger signals during ischemic storage of the liver: a potential marker of organ damage?","volume":"2010","author":"Liu","year":"2010","journal-title":"Mediators Inflamm"},{"key":"R387-1-20210211","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1399-0012.2010.01233.x","article-title":"Extraction time of kidneys during organ procurement impacts function","volume":"25","author":"Osband","year":"2011","journal-title":"Clin Transplant"},{"key":"R388-1-20210211","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/lt.21268","article-title":"Liver transplantation using suboptimal grafts: impact of donor harvesting technique","volume":"13","author":"D\u2019Amico","year":"2007","journal-title":"Liver Transpl"},{"key":"R389-1-20210211","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.3748\/wjg.15.3538","article-title":"Urokinase perfusion prevents intrahepatic ischemic-type biliary lesion in donor livers","volume":"15","author":"Lang","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R390-1-20210211","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1016\/j.transproceed.2009.09.026","article-title":"Biliary strictures after liver transplantation: risk factors and prevention by donor treatment with epoprostenol","volume":"41","author":"Pirenne","year":"2009","journal-title":"Transplant Proc"},{"key":"R391-1-20210211","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/lt.24370","article-title":"Flushing the liver with urokinase before transplantation does not prevent nonanastomotic biliary strictures","volume":"22","author":"Pietersen","year":"2016","journal-title":"Liver Transpl"},{"key":"R392-1-20210211","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/SLA.0000000000000402","article-title":"The effect of preservation solutions for storage of liver allografts on transplant outcomes: a systematic review and meta-analysis","volume":"260","author":"O'Callaghan","year":"2014","journal-title":"Ann Surg"},{"key":"R393-1-20210211","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1600-6143.2006.01595.x","article-title":"Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury","volume":"7","author":"Baskin-Bey","year":"2007","journal-title":"Am J Transplant"},{"key":"R394-1-20210211","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1034\/j.1600-6143.2002.20805.x","article-title":"Successful six-day kidney preservation using trophic factor supplemented media and simple cold storage","volume":"2","author":"McAnulty","year":"2002","journal-title":"Am J Transplant"},{"key":"R395-1-20210211","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4161\/org.5.3.9582","article-title":"Preservation methods for kidney and liver","volume":"5","author":"Lee","year":"2009","journal-title":"Organogenesis"},{"key":"R396-1-20210211","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1111\/j.1600-6143.2011.03731.x","article-title":"Hypothermic reconditioning by gaseous oxygen improves survival after liver transplantation in the pig","volume":"11","author":"Minor","year":"2011","journal-title":"Am J Transplant"},{"key":"R397-1-20210211","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/ajt.12958","article-title":"Hypothermic machine preservation facilitates successful transplantation of \"orphan\" extended criteria donor livers","volume":"15","author":"Guarrera","year":"2015","journal-title":"Am J Transplant"},{"key":"R398-1-20210211","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1586\/17474124.2016.1149061","article-title":"Extended criteria donors in liver transplantation Part I: Reviewing the impact of determining factors","volume":"10","author":"Nemes","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R399-1-20210211","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/lt.24436","article-title":"Normothermic machine perfusion reduces bile duct injury and improves biliary epithelial function in rat donor livers","volume":"22","author":"Op den Dries","year":"2016","journal-title":"Liver Transpl"},{"key":"R400-1-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SLA.0b013e3181a63c10","article-title":"Normothermic perfusion: a new paradigm for organ preservation","volume":"250","author":"Brockmann","year":"2009","journal-title":"Ann Surg"},{"key":"R401-1-20210211","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1523-1755.2005.00573.x","article-title":"Administered mesenchymal stem cells enhance recovery from ischemia\/reperfusion-induced acute renal failure in rats","volume":"68","author":"Lange","year":"2005","journal-title":"Kidney Int"},{"key":"R402-1-20210211","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/CCM.0b013e31823dae23","article-title":"Systemic administration of autologous adipose-derived mesenchymal stem cells alleviates hepatic ischemia-reperfusion injury in rats","volume":"40","author":"Sun","year":"2012","journal-title":"Crit Care Med"},{"key":"R403-1-20210211","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/TP.0b013e31825774d7","article-title":"Hypothermic oxygenated machine perfusion in porcine donation after circulatory determination of death liver transplant","volume":"94","author":"Fondevila","year":"2012","journal-title":"Transplantation"},{"key":"R404-1-20210211","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jhep.2013.11.023","article-title":"HOPE for human liver grafts obtained from donors after cardiac death","volume":"60","author":"Dutkowski","year":"2014","journal-title":"J Hepatol"},{"key":"R405-1-20210211","doi-asserted-by":"crossref","first-page":"e88521","DOI":"10.1371\/journal.pone.0088521","article-title":"Hypothermic oxygenated machine perfusion prevents arteriolonecrosis of the peribiliary plexus in pig livers donated after circulatory death","volume":"9","author":"Op den Dries","year":"2014","journal-title":"PLoS One"},{"key":"R406-1-20210211","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jhep.2013.06.022","article-title":"Hypothermic oxygenated perfusion (HOPE) protects from biliary injury in a rodent model of DCD liver transplantation","volume":"59","author":"Schlegel","year":"2013","journal-title":"J Hepatol"},{"key":"R407-1-20210211","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2015.03.008","article-title":"Machine perfusion in liver transplantation as a tool to prevent non-anastomotic biliary strictures: rationale, current evidence and future directions","volume":"63","author":"Weeder","year":"2014","journal-title":"J Hepatol"},{"key":"R408-1-20210211","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/j.1600-6143.2010.03142.x","article-title":"High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF study","volume":"10","author":"Martinez","year":"2010","journal-title":"Am J Transplant"},{"key":"R409-1-20210211","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1600-6143.2011.03441.x","article-title":"RPSGL-Ig for improvement of early liver allograft function: a double-blind, placebo-controlled, single-center phase II study","volume":"11","author":"Busuttil","year":"2011","journal-title":"Am J Transplant"},{"key":"R410-1-20210211","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1172\/JCI31892","article-title":"Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation","volume":"117","author":"Lang","year":"2007","journal-title":"J Clin Invest"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00007890-201704002-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T16:18:21Z","timestamp":1750177101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201704002-00001"}},"subtitle":["A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group"],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":398,"journal-issue":{"issue":"4S","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001651","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}